Zenas BioPharma (ZBIO) EBT (2023 - 2026)

Zenas BioPharma's EBT history runs 4 years deep, the most recent figure standing at -$81.0 million for Q1 2026.

• In Q1 2026, EBT fell 139.76% year-over-year to -$81.0 million; the TTM figure through Mar 2026 stood at -$435.7 million (down 161.07% YoY), while the FY2025 annual figure was -$388.5 million, down 141.43% from the prior year.
• EBT was -$81.0 million for Q1 2026 at Zenas BioPharma, up from -$251.0 million in the prior quarter.
• In the past five years, EBT ranged from a high of $35.6 million in Q3 2023 to a low of -$251.0 million in Q4 2025.
• Historically, EBT has averaged -$56.3 million across 4 years, with a median of -$38.6 million in 2024.
• Biggest YoY gain for EBT was 21.5% in 2025; the steepest drop was 344.03% in 2025.
• A 4-year view of EBT shows it stood at -$24.8 million in 2023, then tumbled by 128.15% to -$56.5 million in 2024, then sank by 344.03% to -$251.0 million in 2025, then jumped by 67.74% to -$81.0 million in 2026.
• The last three EBT figures came in at -$81.0 million (Q1 2026), -$251.0 million (Q4 2025), and -$51.5 million (Q3 2025), per Business Quant data.